Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q5T6L9
UPID:
EMARD_HUMAN
Alternative names:
-
Alternative UPACC:
Q5T6L9; B4DFH0; F8WAF1; Q3ZCS8; Q5T6L8; Q9NUT5; Q9NVU2
Background:
The Endoplasmic reticulum membrane-associated RNA degradation protein, identified by the accession number Q5T6L9, is implicated in crucial cellular processes. Its primary function may involve facilitating neuronal migration during embryonic development, a critical step in the formation of the central nervous system.
Therapeutic significance:
Linked to Periventricular nodular heterotopia 6, a condition characterized by abnormal neuronal migration leading to seizures and developmental delays, this protein's study offers a pathway to understanding and potentially treating this neurological disorder.